This site is intended for Healthcare professionals only.
×

Lupin receives tentative USFDA nod for Dimethyl Fumarate Delayed-Release Capsules


Lupin receives tentative USFDA nod for Dimethyl Fumarate Delayed-Release Capsules

New Delhi: Lupin announced that it has received tentative approval for its Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg from the United States Food and Drug Administration (FDA).

Lupin’s Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg is the generic version of Biogen, Inc’s Tecfidera Capsules, 120 mg and 240 mg.

It is indicated for the treatment of patients with relapsing forms of multiple sclerosis. It helps to decrease the number of episodes of worsening multiple sclerosis.

Tecfidera belongs to a group of drugs called Nrf2 activators. It is thought to work by decreasing inflammation and preventing nerve damage that can lead to symptoms of multiple sclerosis.
Lupin is a pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

The following two tabs change content below.
MD Team

MD Team

At Medical Dialogues, we are a team of young professionals strongly advocating of the transparency in the medical sector through the free flow of medical information, health and medical news. MD Team covers a variety of news related to the healthcare, pharma and medical device industry in India. Our team can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751


Source: With input
0 comment(s) on Lupin receives tentative USFDA nod for Dimethyl Fumarate Delayed-Release Capsules

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted